Canada· CA-DIN-02464241
VEMLIDY
A tenofovir alafenamide product containing tenofovir alafenamide (tenofovir alafenamide hemifumarate), registered in Canada by GILEAD SCIENCES CANADA INC. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Tenofovir alafenamide is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AF13 (tenofovir alafenamide), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Tenofovir alafenamide · ATC J05AF13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tenofovir alafenamide costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tenofovir alafenamide · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.29
- IT Italy$18.37
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
- Manufacturer
- GILEAD SCIENCES CANADA INC
- Country
- Canada (CA)
- ATC code
- J05AF13
- ATC class
- Tenofovir alafenamide
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tenofovir alafenamide in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomVemlidy 25mg tabletsGilead Sciences Ltd
- United StatesVEMLIDYGilead Sciences, Inc.
- FinlandVemlidyOrifarm Oy
- NorwayVemlidyAbacus Medicine A/S
- CzechiaVEMLIDYGilead Sciences Ireland UC, Carrigtohill
- BelgiumGenvoya 90 mg - 90 mg - 120 mg - 6 mgGilead Sciences Ireland UC
- IrelandVemlidy 25 mg film-coated tabletsGilead Sciences Ireland UC
- IcelandVemlidyGilead Sciences Ireland UC*
Authorised across Europe · EMA
The same active substance is authorised in 6 EEA countries. Names it is sold under:
- Germany · Tenofoviralafenamid Devatis
- Iceland · Vemlidy
- Liechtenstein · Vemlidy
- Netherlands · Tenofoviralafenamide Devatis
- Norway · Vemlidy
- Portugal · Tenofovir Alafenamida Humanis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/46af6e26-ca25-468f-abba-5ccc8ab179cb GET /v1/drugs/46af6e26-ca25-468f-abba-5ccc8ab179cb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02464241",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "J05AF13",
"schedule": [
"Prescription"
],
"drug_code": "95241",
"strengths": [
"25 MG"
],
"ahfs_class": null,
"substances": [
"TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)"
],
"product_categorization": null
}See everything about tenofovir alafenamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.